154589-96-5

154589-96-5 structure

Name: Stauprimide
Chemical Name: Stauprimide
CAS Number: 154589-96-5
Molecular Formula: C₃₅H₂₈N₄O₅
Molecular Weight: 584.621
Catalog: Signaling Pathways Apoptosis c-Myc
Create Date: 2017-07-31 09:33:07
Modify Date: 2024-01-10 16:38:57
Stauprimide is a staurosporine analog that promotes embryonic stem cell (ESC) differentiation. Stauprimide is a non-broad spectrum inhibitor that binds to the MYC transcription factor NME2 and blocks its nuclear localization in ESCs, which results in down-regulation of MYC transcription[1].

Name	Stauprimide
Synonyms	Benzamide, N-[(6S,7R,8R,10R)-7,8,9,10,17,18-hexahydro-7-methoxy-6-methyl-16,18-dioxo-6,10-epoxy-6H,16H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-8-yl]-N-methyl- N-[(2S,3R,4R,6R)-3-Methoxy-2-methyl-16,18-dioxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1.0.0.0.0.0]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-N-methylbenzamid e N-[(2S,3R,4R,6R)-3-Methoxy-2-methyl-16,18-dioxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1.0.0.0.0.0]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-N-methylbenzamide

Description	Stauprimide is a staurosporine analog that promotes embryonic stem cell (ESC) differentiation. Stauprimide is a non-broad spectrum inhibitor that binds to the MYC transcription factor NME2 and blocks its nuclear localization in ESCs, which results in down-regulation of MYC transcription[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Apoptosis >> c-Myc
In Vitro	Stauprimide (10 μM; 6 hours) suppresses MYC transcription in the majority of cell lines tested with an EC50 range of 30 nM-8 μM, and decreases MYC levels between 15% to over 90%[1]. Stauprimide (2-8 μM; 24-72 hours) down-regulates MYC leads to the inhibition of cell proliferation in vitro with an IC50 of 780 nM in RXF 393 cells[1]. Stauprimide (5 μM; 3 hours) suppresses MYC Transcription by decreasing NME2 Nuclear Translocation[1]. Stauprimide (4-10 μM; 6 hours) acts with different EC50s and with different degrees of maximal MYC mRNA down-regulation in different cell lines[1]. Cell Proliferation Assay[1] Cell Line: Renal cancer cell line RXF 393 cells Concentration: 2 μM, 4 μM, 8 μM Incubation Time: 24 hours, 48 hours, 72 hours Result: Inhibited cell proliferation at concentrations of 2-8 μM. Western Blot Analysis[1] Cell Line: Renal cancer cell line RXF 393 cells and CAKI-1 cells Concentration: 5 μM Incubation Time: 3 hours Result: Decreased nuclear localized NME2. RT-PCR[1] Cell Line: CA46 cells; Ramos cells; RXF393 cells; TK10 cells; KG1A cells; CAKI-1 cells Concentration: 4μM, 6μM, 8μM, 10μM Incubation Time: 6 hours Result: Suppressed MYC transcription in KG1A cells with an EC50 of 400±50 nM and a suppression of 90%; CA46 cells were resistant to stauprimide.
In Vivo	Stauprimide (oral administration; 50 mg/kg; once daily; 30 days, 55 days) blocks tumor growth, reduces MYC protein levels in xenograft mouse with RXF 393 or CAKI-1 cells and inhibits MYC transcription in the RXF 393 tumor[1]. Animal Model: Xenograft tumor models with RXF 393 and CAKI-1 cells in NOD/SCID mice[1] Dosage: 50 mg/kg Administration: Oral administration; 50 mg/kg; once daily; 30 days, 55 days Result: Blocked tumor growth in mice injected with either RXF 393 or CAKI-1 cells during the dosing periods.
References	[1]. Bouvard C, et al. Small molecule selectively suppresses MYC transcription in cancer cells. Proc Natl Acad Sci USA. 2017 Mar 28;114(13):3497-3502.

Density	1.5±0.1 g/cm3
Melting Point	145°C
Molecular Formula	C₃₅H₂₈N₄O₅
Molecular Weight	584.621
Exact Mass	584.205994
PSA	98.56000
LogP	6.13
Index of Refraction	1.783
Storage condition	-20°C

RIDADR	NONH for all modes of transport

56-41-7	108-65-6
56-35-9	64-17-5
67-56-1	108-88-3
141-78-6	1310-73-2
13463-67-7	1333-86-4